Salateen Philip

41. Recall Alert: WFI (Batch # W-174), M/s City Pharmaceutical Laboratories (DML#00723)

Salateen Philip Recall Alerts October 19, 2026October 19, 2026Recall

Recall Alert


	DRUG PRODUCT DECLARED SUBSTANDARD & ADULTERATED BY CENTRAL DRUGS LABORATORY KARACHI.

DRAP Alert No	N^oI/S/07-26-36
Action Date	14 July, 2026
Target Audience	– National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Central Drugs Testing Laboratory, Karachi informed that the samples of diluent i.e. Water for Injection (Batch # W-174) in the combo-pack of the below mentioned drug products have been declared as ‘Substandard’ based on presence of visible particles.

Therapeutic Goods (s) Affected: –

Sr. No.	Product Name	Batch Numbers	Manufacturers
1.	Exoran-500mg Injection vial	P-240 P-239	M/s City Pharmaceutical Laboratories, Plot 12-A, I-5, Sector 5, Korangi Industrial Area, Karachi (DML No. 00723).
2.	Exoran-1g Injection vial	P-252 P-251	M/s City Pharmaceutical Laboratories, Plot 12-A, I-5, Sector 5, Korangi Industrial Area, Karachi (DML No. 00723).
3.	Exit 500mg injection	P-829 P-828	M/s City Pharmaceutical Laboratories, Plot 12-A, I-5, Sector 5, Korangi Industrial Area, Karachi (DML No. 00723).
4.	Exit 1g injection	P-1107 P-1106 P-1105 P-1104	M/s City Pharmaceutical Laboratories, Plot 12-A, I-5, Sector 5, Korangi Industrial Area, Karachi (DML No. 00723).

The details of Substandard water for injection ire as follows:

Sr. No.	Product Name	Batch No.	Manufacturers	Remarks
1.	Water for Injection	W-174	M/s City Pharmaceutical Laboratories, Plot 12-A, I-5, Sector 5, Korangi Industrial Area, Karachi (DML No. 00723).	The sample has been declared as “Substandard” based on presence of particles visible to naked eye.

Risk Statement:	TThese findings indicate a high public health risk, primarily affecting hospitalized patients and vulnerable groups. The most likely to be harmed are neonates, children, elderly patients, immunocompromised individuals, post-surgical patients, and those receiving IV therapy. Substandard Water for injection containing particles visible to the naked eye may cause bloodstream infections, septic or pyrogenic reactions, and potentially fatal complications. Particles may also contribute to embolic or inflammatory complications. The greatest risk is in intensive care, emergency, and other clinical settings where sterile injectable products are essential.
Action Initiated	The field force of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.
Advice for Healthcare Professionals	DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above-mentioned products along with the other drug products containing Water For Injection (Batch No.: W-174) are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information about reporting problems to DRAP is available on this link.
Advice for Pharmacies/Medical stores: –	All pharmacists and chemists working at distributions and pharmacies should immediately check their stocks and stop supplying mentioned products along with the other drug products containing Water For Injection (Batch No.: W-174). The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).
Advice for Consumers	Consumers should stop using products bearing the affected batch number(s) and containing water for injection (Batch No.: W-174) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using the drug products, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.

40. Rapid Alert: Spurious/Falsified Nasomet Aqueous Nasal Spray, Batch No. FW-099

Salateen Philip Recall Alerts October 19, 2026October 19, 2026RapidAlert

Download

Rapid Alert


	Spurious/Falsified Nasomet Aqueous Nasal Spray (Mometasone Furoate 50 mcg/spray), Batch No. FW-099

DRAP Alert No	N^o I/S/10-26-40
Action Date	19 October, 2026
Target Audience	Regulatory Field Force of DRAP and Provincial Drug Control departments. Healthcare Professionals Consumers
Problem Statement	Central Drugs Laboratory, Karachi declared the following sample as Spurious/Falsified under Section 3(z-b) (ii) & 3(z-b) (ii) of the Drugs Act, 1976 The sample was referred to CDL, Karachi, by the Area Federal Inspector of Drugs, Karachi, on the grounds that it was suspected to be spurious. M/s Sante Sante (Private) Limited, A-97, SITE Superhighway, Karachi, has disowned the sample, stating that it does not belong to or originate from the said manufacturer.

S#	Product Name	Batch	Manufacturer (as per label)	Test Result
1	Nasomet Aqueous Nasal Spray Each Spray Contains: Mometasone Furoate …. 50 mcg (Reg # 108661)	FW-099	*Purported to be manufactured by:* M/s Sante (Private) Limited (DML # 000702) A-97, SITE Superhighway, Karachi.	Declared Spurious / falsified (Mometasone furoate not identified)

Risk Statement	Use of this product may result in treatment failure due to the absence of the declared active ingredient and may pose potential risks to patient safety.
Action Initiated	The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.
Advice for Healthcare Professionals	DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.
Advice for Consumers	Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

39. Rapid Alert . SPURIOUS AND UNREGISTERED ONCOLOGY PRODUCTS

Salateen Philip Recall Alerts July 29, 2026July 29, 2026RapidAlert

Download

Rapid Alert


	SPURIOUS AND UNREGISTERED ONCOLOGY PRODUCTS IDENTIFIED BY THE DRUG TESTING LABORATORY, SINDH (KARACHI)

DRAP Alert No	N^o I/S/07-26-39
Action Date	29 July, 2026
Target Audience	National Regulatory Field Force of DRAP and Provincial Drug Control Departments. Healthcare Professionals (Oncologists, Hematologists, Pharmacists & Nurses). Hospitals and Oncology Treatment Centres. General Public.
Problem Statement	The Drug Testing Laboratory Sindh, Karachi, under the Provincial Government Analyst, has reported the following oncology drug products were declared Spurious/unregistered, as laboratory identification confirmed the absence of the declared active pharmaceutical ingredient, as defined under Section 3(z)(b)(i) read with Section 23(1)(a)(i) & (vii) of the Drugs Act, 1976.

S#	Product	Batch No.	Manufacturer	Identification Result	Classification
1	Leukeran-2mg Tablet	512900	Excella GmbH & Co. KG, Feucht, Germany	Chlorambucil (confirmed)	Unregistered
2	Sarafenib/Sorafenib-200mg Tablet (Soraclog)	GST56925-C	Globela Pharma (Pvt) Ltd, Surat, India	Sorafenib Tosylate — Not Identified	Spurious & Unregistered
3	Arimidex-1mg Tablet	B2417	Haupt Pharma Münster GmbH, Germany	Anastrozol (confirmed)	Unregistered
4	Lenvaxen 4 Capsule	26ALV04004	Everest Pharmaceutical Ltd, Narayanganj, Bangladesh	Lenvatinib Mesylate (confirmed)	Unregistered
5	Cyclophosphamide-50mg Tablet	OT0470	Kwality Pharmaceutical Ltd, Kangra, India	Cyclophosphamide not Identified	Spurious & Unregistered
6	Gefimed-250mg Tablet	25GST016	Globela Pharma (Pvt) Ltd, Surat, India	Gefitinib (confirmed)	Unregistered
7	Lenvatinib-10mg Capsule (Lenvalieva)	C25LN03B3	Allieva Pharma (Pvt) Ltd, Baddi, Himachal Pradesh, India	Lenvatinib Mesylate (confirmed)	Unregistered
8	Lenalidomide-10mg Capsule	OC0090	Kwality Pharmaceutical Ltd, Kangra, India	Lenalidomide (confirmed)	Unregistered
9	Nintedanib Soft Gelatin Capsule (Nindanib 150)	24250052	Glenmark Pharmaceuticals Ltd, Daman, India	Nintedanib Ethanesulfonate (confirmed)	Unregistered

Risk Statement	These are high-value oncology therapeutics (chemotherapy, targeted kinase inhibitors, and hormonal cancer agents) used for the treatment of leukaemia, breast cancer, hepatocellular carcinoma, renal cell carcinoma, multiple myeloma, and related malignancies. Unregistered products have bypassed DRAP’s quality, safety, and efficacy evaluation and therefore carry unverified risk. In the products declared spurious, laboratory testing found the stated active ingredient was not identified, meaning the product may deliver no therapeutic effect at all. Use of these products in cancer patients by an already immunocompromised and vulnerable population may result in treatment failure, disease progression, and potentially life-threatening outcomes.
Action Initiated	The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.
Advice for Healthcare Professionals	DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.
Advice for Consumers	Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

38. Rapid Alert – Falsified JAKAVI® (Ruxolitinib) Tablets

Salateen Philip Recall Alerts July 16, 2026July 16, 2026RapidAlert

Download

Rapid Alert


	Falsified JAKAVI® (Ruxolitinib) Tablets Identified in the WHO Eastern Mediterranean and European Regions

DRAP Alert No	N^o I/S/07-26-38
Action Date	16 July, 2026
Target Audience	National Regulatory Field Force of DRAP and Provincial Drug Control Departments. Healthcare Professionals (Oncologists, Hematologists, Pharmacists & Nurses). Hospitals and Oncology Treatment Centres. General Public.
Problem Statement	The Drug Regulatory Authority of Pakistan (DRAP) has received WHO Medical Product Alert No. 2/2026 regarding falsified JAKAVI® (ruxolitinib) tablets identified in the WHO Eastern Mediterranean and European Regions. The falsified products were detected in the Islamic Republic of Iran, Türkiye, and the Russian Federation after being illicitly sold through online platforms and, in at least one instance, supplied through a pharmacy. The genuine manufacturer, Novartis Pharma AG, has confirmed that the following batch numbers are not genuine. Any JAKAVI® product bearing these batch numbers should be considered falsified and should not be used.

S#	Name of Product	Batch No.	Manufacturer Details	Remarks
1	JAKAVI® (Ruxolitinib) Tablets 20 mg	AVT50	Manufacturer: Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland	Falsified Product
2	JAKAVI® (Ruxolitinib) Tablets 15 mg	FNR06	Manufacturer: Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland
3	JAKAVI® (Ruxolitinib) Tablets 15 mg	SGL04	Manufacturer: Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland

Risk Statement	JAKAVI® (ruxolitinib) is indicated for the treatment of myelofibrosis, polycythaemia vera, and graft-versus-host disease following stem cell transplantation. The identified products are falsified medical products. Novartis has confirmed that the above-mentioned batch numbers are not valid. Laboratory analysis of a sample from batch AVT50 confirmed the absence of the declared active ingredient (ruxolitinib). Additionally, visual discrepancies were identified in the packaging, including the absence of batch numbers on blister strips of certain falsified batches. Use of these falsified products may result in treatment failure, disease progression, increased morbidity, and potentially life-threatening outcomes. Patients receiving JAKAVI® often have compromised immune systems, making them particularly vulnerable to ineffective or falsified medicines.
Action Initiated	The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.
Advice for Healthcare Professionals	DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.
Advice for Consumers	Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

37. Rapid Alert – Falsified DARZALEX (Daratumumab) Injection

Salateen Philip Recall Alerts July 16, 2026July 16, 2026RapidAlert

Download

Rapid Alert


	Falsified DARZALEX (Daratumumab) Injection Identified in WHO Regions of the Americas and South-East Asia

DRAP Alert No	N^o I/S/07-26-37
Action Date	16 July, 2026
Target Audience	National Regulatory Field Force of DRAP and Provincial Drug Control Departments. Healthcare Professionals (Oncologists, Hematologists, Pharmacists & Nurses). Hospitals and Oncology Treatment Centres. General Public.
Problem Statement	The Drug Regulatory Authority of Pakistan (DRAP) has received a Medical Product Alert No. 3/2026 issued by the World Health Organization (WHO) regarding falsified DARZALEX (Daratumumab) Injection identified in the WHO Regions of the Americas and South-East Asia. The falsified products were detected in Maldives and Mexico after being supplied through non-authorized distributors, with at least one report indicating supply to hospitals. The genuine manufacturer, JANSSEN, has confirmed that the following batch numbers are not valid and any DARZALEX product bearing these batch numbers should be considered falsified.

S#	Name of Product	Batch No.	Stated Manufacturer	Remarks
1	DARZALEX (Daratumumab) Injection 400 mg/20 mL	STV1K01	Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium.	Falsified Product
2	DARZALEX (Daratumumab) Injection 100 mg/5 mL	MYS7381		Falsified Product

Risk Statement	DARZALEX (daratumumab) is a monoclonal antibody indicated for the treatment of multiple myeloma and amyloid light-chain (AL) amyloidosis. No laboratory testing has been performed on the falsified products and their identity, composition, quality, and sterility remain unknown. These products may contain no active ingredient, incorrect ingredients, or harmful substances, making them ineffective or potentially dangerous. WHO has also reported the presence of visible particulate matter in one falsified batch (STV1K01), indicating a potential risk of contamination. Use of these products may result in treatment failure, disease progression, infections, injection-related complications, increased morbidity, and potentially life-threatening outcomes.
Action Initiated	The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.
Advice for Healthcare Professionals	DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.
Advice for Consumers	Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

36. Recall Alert – Medical Devices Declared Substandard by CDL Karachi

Salateen Philip Recall Alerts July 14, 2026July 14, 2026Recall

Recall Alert

Download


	MEDICAL DEVICES DECLARED SUBSTANDARD BY CENTRAL DRUG LABORATORY KARACHI

DRAP Alert No	N^oI/S/07-26-36
Action Date	14 July, 2026
Target Audience	– National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Central Drugs Laboratory (CDL), Karachi has informed that samples of the below-mentioned Medical Devices have been declared “Substandard”.

Therapeutic Goods (s) Affected: –

S#	Product Name	Batch No.	Manufacturer / Importer details	Remarks
1	BD 10ML Syringe (MDMR-0000035)	5349764	Manufacturer: Becton Dickinson Medical (S) Pte. Ltd. 30 Tuas Avenue 2, Singapore. Importer: M/s Asto Life Sciences (Pvt.) Ltd. Plaza #1, Block Orchard-1, Gate #2, Paragon City, Barki Road, Lahore. (ELI-00103)	Substandard on the basis of Absorbance test.
2.	Accuject Auto-Disable Syringe 5ml (MDMR-000507)	S502E26	Manufacturer: M/s Faiz Surgical and Medical Industries (Pvt.) Ltd. Plot No. 540-B, Sundar Industrial Estate, Lahore. (ELM-0093)	Substandard on the basis of Sterility test.

Risk Statement:	The affected batches have been declared substandard due to failure of critical quality tests. The BD 10 mL Syringe (Batch No. 5349764) failed the Absorbance test, indicating excessive extractable substances that may compromise product safety and quality for parenteral use. The Accuject Auto-Disable Syringe 5 mL (Batch No. S502E26) failed the Sterility test, indicating possible microbial contamination that may increase the risk of infection, including serious systemic infections, upon use.
Action Initiated	-The field force of DRAP and Provincial Drug Control Departments has been directed to immediately conduct market surveys for detection of presence and removal of the affected batches from the market. Manufacturers, importers and distributors have been directed to initiate recall of the affected batches in accordance with applicable regulatory requirements. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned batches of the drug product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.
Advice for Pharmacies/Medical stores: –	All pharmacists and chemists working at distributions and pharmacies should immediately check their stocks and stop supplying the above-mentioned batches. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units should also increase surveillance in the market to ensure effective recall of the affected products.
Advice for Consumers	Consumers and healthcare facilities in possession of the affected batches should immediately stop using these products and contact the supplier, distributor or manufacturer for return or replacement. Any adverse event or quality issue associated with the use of these products should be reported to DRAP/National Pharmacovigilance Centre.

35. Recall Alert – DTL Punjab Declared Substandard Drug Products.

Salateen Philip Recall Alerts June 18, 2026June 18, 2026Recall

Recall Alert

Download


	DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL LABORATORIES

DRAP Alert No	N^oI/S/06-26-35
Action Date	18 June, 2026.
Target Audience	– National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Drug Testing Laboratories (DTL) Punjab informed that the samples of below mentioned drug products have been declared as ‘Substandard/Adulterated’.

Therapeutic Goods (s) Affected: –

S#	Product Name	Batch	Manufacturers	Remarks
1.	Neocobal 0.5 mg Injection Each ml contains: Mecobalamin ……..0.5mg (Reg. # 071447)	S-3052	M/s Pulse Pharmaceuticals (Pvt) Ltd. Mozay Badoke Raiwind Road (Sua Asil Road) Lahore. (DML # 000564)	The sample is declared as “sub-standard” on the basis of Assay Test & “adulterated” as per section 3 (a) (iv) of The Drugs Act 1976 (Cyanocobalamin is Identified).
2.	GAMMARAAS Injection Immune Globulin Injection (Human) 5%, 2.5g, 50ml/vial (Reg. # 031350)	202311G042	*Imported & Distributed by* Popular International (Pvt.) Ltd. 141, Justice Inamullah Road, Block 7 & 8 KMCHS, Karachi.	The sample is declared as “sub-standard” with regards to Description & Sterility test.
3.	Injection. KAMEDEX 1mL Each ml contains: Dexamethasone Sodium Phosphate eq. to Dexamethasone phosphate 4 mg (Reg. # 074983)	DX-2642	M/s Amaan Pharma. 30-Km Sheikhupura Road Lahore (DML # 000808)	The sample has been declared Adulterated as per Section 3 (a) (v) of The Drugs Act 1976 (label claims Dexamethasone Sodium Phosphate equivalent to Dexamethasone Phosphate 4 mg/mL, laboratory analysis identified Dexamethasone base at a much lower level, rendering the composition false and misleading).
4.	BRZOLE 500mg/100ml Infusion Each vial contains: Metronidazole….500mg/100ml (Reg. # 099612)	25055	M/s Berlex Lab. International, 10-Km Nangshah Chowk Karachi Road Multan (DML # 000678)	The sample is declared as “sub-standard” with regards to Bacterial Endotoxin test.
5.	Metrorise Infusion Metronidazole….500mg/100ml (Reg. # 040412-D)	LV-2514	M/s Pak Risen Pharmaceuticals. Plot No. 3 Block B Phase-I-II Industrial Estate Hattar. (DML # 000573)	The sample has been declared “Substandard” on the basis of Bacterial Endotoxin Test & Visible particles.
6.	Murcobal Injection 500 mcg Each ml Contains Mecobalamin…500mcg (Reg. # 045904)	109	M/s Murfy Pharmaceuticals (Pvt) Ltd. 8-Km Raiwind Road Lahore. (DML # 000543)	The sample is declared as “sub-standard” on the basis of Assay Test & “adulterated” as per section 3 (a) (iv) of The Drugs Act 1976 (Cyanocobalamin is Identified).
7.	Premvil Infusion 1gm/100 ml Each l00ml contains: Paracetamol………….1gm (Reg. # 125218)	PNO-2510	Ahad International Pharmaceutical LTD 13-Km, Multan Road, Dera Ismail Khan	The sample is declared as “sub-standard” with regards to Visible Particulates
8.	Aqua-P Injection Sterile water for injection 5ml	P-673	M/s Ipram International. Plot # 26 SS-3 National Industrial Zone Rawat. (DML # 000551)	Sub-standard’ on the basis of Bacterial Endotoxin Test.
9.	ZYOCAIN Gel Lignocaine Hydrochloride B.P 2% w/v (Reg # 012523)	008	M/s PharmaWise Labs (Pvt) Ltd. 25-M Industrial Area Kot Lakhpat Lahore. (DML # 000182)	Sub-standard’ on the basis of Sterility test
10.	Injection Cara-Lac 30mg/1ml Each 1ml contains: – Ketorolac Tromethamine equivalent to Ketorolac………30mg (Reg. # 054997)	25G022	M/s Caraway Pharmaceuticals. Plot No. 12 Street No. N-3 National Industrial Zone (RCCI) Rawat. (DML # 000629)	The sample is declared as “sub-standard” on the basis of Test for Impurities i.e. Organic Impurities.
11.	Sterile Water for Injection 5ml	20334	M/s NovaMed Pharmaceuticals (Pvt) Ltd. 28-Km Ferozepur Road Lahore (DML # 000590)	Sub-standard’ on the basis of Bacterial Endotoxin Test.

Risk Statement:	The affected products have been found to possess critical quality defects, including failure of sterility, bacterial endotoxin, assay, impurity, and visible particulate tests, while certain products were also declared adulterated due to misidentified active ingredients or misleading composition. Use of these products may result in treatment failure, serious infections, pyrogenic reactions, adverse health effects, or other patient safety risks. Healthcare professionals, distributors, and retailers are therefore advised to immediately cease distribution and use of the affected batches and ensure their prompt recall from the market.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

34- Recall Alert- DTL Sindh declared Substandard Auto Disable Syringes

Salateen Philip Recall Alerts June 8, 2026June 8, 2026Recall

Recall Alert

Download


	MEDICAL DEVICES DECLARED SUBSTANDARD BY PROVINCIAL LABORATORIES

DRAP Alert No	N^oI/S/06-26-34
Action Date	08 June, 2026
Target Audience	– National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Drug Testing Laboratory Sindh, Karachi has informed the Drug Regulatory Authority of Pakistan that samples of the below-mentioned medical devices have been declared “Substandard” due to failure of the Self-Destructive Performance / Auto-Disability Test (re-use prevention feature).

Therapeutic Goods (s) Affected: –

S#	Product Name	Manufacturer / Importer & Address	Batch No.	Remarks
1	Clinic Auto Disable Syringe 3ml (MDMR-000115)	M/s Surgi Plast Pvt. Ltd., Plot # 78, Road No. L-4, Industrial Estate Gadoon Amazai, Swabi, Khyber Pakhtunkhwa, Pakistan (ELM # 0030)	3-01B-26	Declared Substandard on the basis of failure of Self-Destructive Performance / Auto-Disability Test (re-use prevention feature).
2.	Medi Aqua Auto Disable Syringe 3ml (MDMR-000145)	M/s Frontier Pharmaceutical (Pvt.) Ltd., (ELM # 0042) W-10, Industrial Estate, Jamrud Road, Peshawar, Pakistan	AD1B25	Declared Substandard on the basis of failure of Self-Destructive Performance / Auto-Disability Test (re-use prevention feature).
3.	Ultra Fine SMD Painless 3ml Syringe (MDMR-000229)	M/s Sehat Medical Devices (Pvt.) Ltd., Plot # 473, Sundar Industrial Estate, Lahore, Pakistan (ELM # 0065)	3088CL & 3090CL & 3013DC	Declared Substandard on the basis of failure of Self-Destructive Performance / Auto-Disability Test (re-use prevention feature).

Risk Statement:	Auto-disable and auto-destruct syringes are designed to become permanently inoperable after a single use. Failure of the self-destructive mechanism may permit reuse of the device, increasing the risk of transmission of blood-borne pathogens Auto-disable and auto-destruct syringes are designed to become permanently inoperable after a single use. Failure of the self-destructive mechanism may permit reuse of the device, increasing the risk of transmission of blood-borne pathogens including Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV). Reuse of such defective syringes may also result in cross-contamination, healthcare-associated infections and serious public health consequences, particularly during immunization programmes and other invasive medical procedures.
Action Initiated	The field force of DRAP and Provincial Drug Control Departments has been directed to immediately conduct market surveys for detection of presence and removal of the affected batches from the market. Manufacturers, importers and distributors have been directed to initiate recall of the affected batches in accordance with applicable regulatory requirements.
Advice for Healthcare Professionals	DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned batches of the drug product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.
Advice for Pharmacies/Medical stores: –	All pharmacists and chemists working at distributions and pharmacies should immediately check their stocks and stop supplying the above-mentioned batches. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units should also increase surveillance in the market to ensure effective recall of the affected products.
Advice for Consumers	Consumers and healthcare facilities in possession of the affected batches should immediately stop using these products and contact the supplier, distributor or manufacturer for return or replacement. Any adverse event or quality issue associated with the use of these products should be reported to DRAP/National Pharmacovigilance Centre.

33. Rapid Alert – SPURIOUS DRUG PRODUCTS (NOVIDAT 500MG Tablets and TONOFLEX-P Tablets)

Salateen Philip Recall Alerts June 3, 2026June 3, 2026RapidAlert

Download

Rapid Alert


	SPURIOUS DRUG PRODUCTS (NOVIDAT 500MG Tablets and TONOFLEX-P Tablets)

DRAP Alert No	N^o I/S/06-26-33
Action Date	03 June, 2026
Target Audience	1. Regulatory Field Force of DRAP and Provincial Drug Control departments. 2. Healthcare Professionals 3. Pharmacies and medical stores
Problem Statement	The Drug Regulatory Authority of Pakistan (DRAP) has received test and analysis reports from the Provincial Drug Testing Laboratory, Punjab, regarding the following drug products sampled from the market. The laboratory has declared the products Spurious under Section 3(zb)(i) of the Drugs Act, 1976. Further investigation conducted by the manufacturer, SAMI Pharmaceuticals (Pvt.) Ltd., confirmed that the products were not manufactured by the company and are falsified/spurious.

S#	Product Name	Batch	Manufacturer	Remarks
1	NOVIDAT 500mg Tablets Ciprofloxacin HCl equivalent to Ciprofloxacin 500mg (Reg. No. 011837)	139N086	*Purportedly manufactured under license of* SAMI Pharmaceuticals (Pvt.) Ltd., Karachi	Spurious. Assay result showed 0.00 mg/tablet against the stated strength of 500 mg/tablet.
2	TONOFLEX-P Tablets Tramadol HCl 37.5mg + Paracetamol 325mg (Reg # 067163)	248N105		Spurious. Assay results showed 0.00 mg/tablet for both active ingredients against the stated strengths of 37.5 mg and 325 mg, respectively.

Risk Statement	The presence of spurious medicines containing no detectable active pharmaceutical ingredients poses a serious risk to public health due to treatment failure, disease progression, and potential harm to patients relying on these products. Healthcare professionals and supply chain stakeholders are advised to remain vigilant and immediately report any information regarding the availability or distribution of the above-mentioned batches.
Action Initiated	The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.
Advice for Healthcare Professionals	DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.
Advice for Consumers	Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

32. Rapid Alert – SPURIOUS / FALSIFIED DANZEN DS TABLETS

Salateen Philip Recall Alerts June 2, 2026June 2, 2026RapidAlert

Download

Rapid Alert


	SPURIOUS / FALSIFIED DANZEN DS TABLETS

DRAP Alert No	N^o I/S/06-26-31
Action Date	02 June, 2026
Target Audience	1. Regulatory Field Force of DRAP and Provincial Drug Control departments. 2. Healthcare Professionals 3. Pharmacies and medical stores
Problem Statement	Drug Testing Laboratory (DTL), Government of Punjab has reported that the sample of the following drug product has been declared SPURIOUS under Section 3(z-b)(i) & (ii) of the Drugs Act, 1976, based on the laboratory findings and confirmation received from the manufacturer.

S#	Product Name	Batch	Manufacturer	Remarks
1	DANZEN® DS Tablets (Serratiopeptidase 10 mg) Reg. No. 028173	4476	*Purportedly manufactured under license of* Helix Pharma (Pvt.) Ltd., Karachi.	Declared Spurious by DTL; Serratiopeptidase not identified; Assay 0%; Manufacturer has confirmed the sample was not manufactured by Helix Pharma and has disowned the batch.

Helix Pharma (Pvt.) Ltd. has formally communicated to the regulatory authorities that the submitted sample was not manufactured by the company. Following a comparative investigation against its reference sample.

S.#	Parameters	Reference Sample (Danzen DS 10mg Batch No. 4476)	Manufacturer Portion / spurious (Danzen DS 10mg Batch No. 4476)
01	Color of Tablet	Color of tablet observed dark pink with smooth coating as compare to Warrantor sample.	Color of tablet observed different.
02	Color of Blister Strip	Color of blister observed Blue.	Color of blister observed different as dark blue.
03	Font size and Style of Embossed Batch number and Expiry	Font size and style of embossed batch number and expiry observed as per standard font size.	Font size and style of embossed batch number and expiry observed different as compare to reference standard sample.

Risk Statement	Laboratory analysis conducted by Drug Testing Laboratory, Punjab revealed that Serratiopeptidase, the declared active pharmaceutical ingredient, could not be identified in the tested sample. Assay testing demonstrated complete absence of the declared active ingredient, with results showing 0.0 mg/tablet against the labeled claim of 10 mg/tablet. Use of this counterfeit/spurious product may result in: Complete therapeutic failure. Failure to achieve the intended anti-inflammatory effect. Delay in appropriate treatment and recovery. Exposure to unknown or undeclared ingredients of uncertain quality, safety and efficacy. Potential adverse health consequences arising from the use of falsified medicines.
Action Initiated	The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.
Advice for Healthcare Professionals	DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.
Advice for Consumers	Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

← Previous